Hepatic safety of caspofungin during treatment of invasive fungal diseases in elderly patients  

作　　者：WANG Li-li ZHUGE Xin XIAO Guang-hui ZHANG Yun 

机构地区：[1]Department of Geriatrics,General Hospital of Tianjin Medical University,Tianjin 300052,China

出　　处：《Chinese Medical Journal》2012年第12期2240-2240,共1页中华医学杂志（英文版）

摘　　要：To the Editor： Caspofungin is a new class of antifungal agents （echinocandins） for the treatment of fungal infections. Bynoncompetitive inhibition β-（1,3）-D-glucan synthase, it can destroy the glucan synthesis of the fungal cell wall and produce bactericidal activity. β-（1,3）-D-glucan does not exist in mammalian cells; thus the toxicity of this drug could be avoided.1 In a recent meta analysis on tolerance and liver toxicity of antifungal agents, Wang et al2 showed that caspofungin had less side effects and better hepatic safety than the other antifungal agents. The pooled risks of treatment discontinuation due to adverse reactions were above 13.4% for amohotericin B.To the Editor： Caspofungin is a new class of antifungal agents （echinocandins） for the treatment of fungal infections. Bynoncompetitive inhibition β-（1,3）-D-glucan synthase, it can destroy the glucan synthesis of the fungal cell wall and produce bactericidal activity. β-（1,3）-D-glucan does not exist in mammalian cells; thus the toxicity of this drug could be avoided.1 In a recent meta analysis on tolerance and liver toxicity of antifungal agents, Wang et al2 showed that caspofungin had less side effects and better hepatic safety than the other antifungal agents. The pooled risks of treatment discontinuation due to adverse reactions were above 13.4% for amohotericin B.

分 类 号：R519[医药卫生—内科学]